title: Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.
abstract: Non-Hodgkin lymphoma symbolizes a heterogeneous group of diseases resulting from malignant transformation of lymphocytes with differing patterns of behavior and responses to treatment. The potential curability of non-Hodgkin lymphoma differs among the various histologic subtypes and is associated in part with the stage at presentation. CD19 antigen is a type I transmembrane glycoprotein belonging to the immunoglobulin Ig superfamily. CD19 is specifically expressed in normal and neoplastic B-cells. Recent study showed that in a mouse model, CD19 and c-Myc synergize functionally to accelerate B-cell lymphomagenesis, which is associated with increased disease severity. Specificity is the most important challenge in cancer therapeutics. Antibody-drug conjugates have the prospect of enhancing the therapeutic efficacy over unconjugated monoclonal antibodies through the selective delivery of cytotoxic agents to cancer cells. The ubiquitous expression of CD19 in these tumors, especially at an earlier stage and the property of efficient internalization, makes CD19 an attractive and affective target for antibody-drug conjugate therapy as compared to CD20. SAR3419 (huB4-DM4) is a novel antibody-drug conjugate that is composed of a humanized monoclonal IgG1 anti-CD19 antibody (huB4) attached to the potent cytotoxic drug, a maytansine derivative (DM4), through a cleavable disulfide cross-linking agent N-Succinimidyl-4-2-pyridyldithio butanoic acid (SPDB). The preclinical efficacy of maytansine derivative-anti-CD19 conjugate was demonstrated in our laboratory, and SAR3419 was found to be more effective than CHOP in a xenograft model. Phase I trials have also been conducted on the basis of preclinical studies that demonstrated promising antitumor activity with acceptable safety results in human B-cell lymphoma models. Additional trials are ongoing and will provide additional insight into the full potential of this novel drug.
authors.affiliation: Lymphoma Research Laboratory, Wayne State University School of Medicine (WSU-SOM), Gordon Scott Hall for Basic Medical Sciences, Detroit, MI, USA.
authors.forename: Ali
authors.initials: A
authors.lastname: Raufi
authors.forename: Abdul Shukkur
authors.initials: AS
authors.lastname: Ebrahim
authors.forename: Ayad
authors.initials: A
authors.lastname: Al-Katib
keywords: SAR3419; antibody-drug conjugates (ADC); lymphoma; maytansinoids; microtubule inhibitors
references.citation: Cancer. 1992 Mar 15;69(6):1468-74
references.pmid: 1540884
references.citation: Blood. 2003 Jan 1;101(1):6-14
references.pmid: 12393429
references.citation: Br J Haematol. 2003 Jun;121(5):749-57
references.pmid: 12780789
references.citation: Nat Biotechnol. 2005 Sep;23(9):1137-46
references.pmid: 16151407
references.citation: J Am Chem Soc. 1972 Feb 23;94(4):1354-6
references.pmid: 5062169
references.citation: Clin Cancer Res. 2010 Aug 1;16(15):3998-4004
references.pmid: 20542986
references.citation: Curr Opin Chem Biol. 2010 Aug;14(4):529-37
references.pmid: 20643572
references.citation: Cancer Treat Rep. 1978 Mar;62(3):425-8
references.pmid: 348310
references.citation: Nat Rev Cancer. 2001 Nov;1(2):118-29
references.pmid: 11905803
references.citation: Blood. 2005 Dec 1;106(12):3725-32
references.pmid: 16123223
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4038-45
references.pmid: 19509168
references.citation: Cancer Res. 2006 Mar 15;66(6):3214-21
references.pmid: 16540673
references.citation: J Clin Oncol. 2012 Aug 1;30(22):2776-82
references.pmid: 22753910
references.citation: Semin Immunol. 2008 Feb;20(1):43-8
references.pmid: 18243730
references.citation: Cancer. 1989 Sep 1;64(5):1041-8
references.pmid: 2527086
references.citation: Drug Discov Today. 2003 Jun 1;8(11):503-10
references.pmid: 12818520
references.citation: N Biotechnol. 2011 Sep;28(5):518-29
references.pmid: 21473941
references.citation: Semin Oncol. 2003 Apr;30(2):110-5
references.pmid: 12720118
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6448-58
references.pmid: 22003072
references.citation: Leuk Res. 1988;12(10):833-43
references.pmid: 3143865
references.citation: Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7
references.pmid: 6961453
references.citation: Blood. 2008 Jan 15;111(2):558-65
references.pmid: 17962512
references.citation: Neoplasia. 2009 May;11(5):448-58, 2 p following 458
references.pmid: 19412429
references.citation: Leuk Lymphoma. 1995 Aug;18(5-6):385-97
references.pmid: 8528044
references.citation: Adv Exp Med Biol. 2005;560:125-39
references.pmid: 15934172
references.citation: N Engl J Med. 2010 Nov 4;363(19):1812-21
references.pmid: 21047225
references.citation: N Engl J Med. 2005 Feb 3;352(5):441-9
references.pmid: 15689582
references.citation: Blood. 2004 Sep 1;104(5):1258-65
references.pmid: 15126323
references.citation: Clin Cancer Res. 2013 Apr 1;19(7):1795-805
references.pmid: 23426279
references.citation: Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080
references.pmid: 18451130
references.citation: Blood. 2002 May 15;99(10):3554-61
references.pmid: 11986207
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Nat Rev Immunol. 2006 Apr;6(4):283-94
references.pmid: 16557260
references.citation: J Immunol. 1992 Nov 1;149(9):2841-50
references.pmid: 1383329
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references.pmid: 16754935
references.citation: J Clin Invest. 2012 Jun;122(6):2257-66
references.pmid: 22546857
references.citation: Blood. 1994 Jan 15;83(2):435-45
references.pmid: 7506951
references.citation: J Clin Oncol. 2008 May 10;26(14):2258-63
references.pmid: 18413640
references.citation: Annu Rev Immunol. 2004;22:55-79
references.pmid: 15032574
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Blood. 2009 Apr 30;113(18):4352-61
references.pmid: 19147785
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6389-97
references.pmid: 22003066
references.citation: J Immunol. 2012 Sep 1;189(5):2318-25
references.pmid: 22826319
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8620-9
references.pmid: 15623646
references.citation: Ann Oncol. 2006 May;17 Suppl 4:iv31-2
references.pmid: 16702182
references.citation: J Natl Cancer Inst. 1978 Jan;60(1):93-6
references.pmid: 628025
references.citation: Blood. 2005 Feb 15;105(4):1417-23
references.pmid: 15494430
references.citation: Proc Natl Acad Sci U S A. 1982 Dec;79(24):7837-41
references.pmid: 6818551
references.citation: Cancer Treat Rep. 1978 Mar;62(3):429-33
references.pmid: 348311
references.citation: Blood. 1984 Jun;63(6):1424-33
references.pmid: 6609729
references.citation: J Immunol. 1983 Jul;131(1):244-50
references.pmid: 6408173
references.citation: Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):975-82
references.pmid: 20970029
references.citation: Cancer Treat Rep. 1978 Mar;62(3):435-8
references.pmid: 348312
references.citation: N Engl J Med. 2006 May 4;354(18):1901-12
references.pmid: 16672701
references.citation: Cancer Res. 2006 Apr 15;66(8):4426-33
references.pmid: 16618769
references.citation: Nat Rev Clin Oncol. 2011 Feb;8(2):85-96
references.pmid: 21151205
references.citation: Nat Rev Rheumatol. 2009 Oct;5(10):572-7
references.pmid: 19798033
references.citation: Cancer Treat Rev. 1978 Dec;5(4):199-207
references.pmid: 367597
references.citation: Nat Rev Clin Oncol. 2011 Mar;8(3):124
references.pmid: 21480559
references.citation: Curr Opin Immunol. 1999 Oct;11(5):584-8
references.pmid: 10508711
references.citation: Cancer Biother Radiopharm. 1997 Aug;12(4):223-5
references.pmid: 10851468
references.citation: Cancer Genet Cytogenet. 1993 Oct 1;70(1):62-7
references.pmid: 8221615
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Ann Oncol. 2012 Feb;23(2):415-20
references.pmid: 21536660
references.citation: Science. 1975 Sep 19;189(4207):1002-5
references.pmid: 1241159
references.citation: Blood. 2004 Jun 15;103(12):4416-23
references.pmid: 14976046